Jaguar Animal Health Inc

Jaguar Health, Inc. is a pharmaceutical company that develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal disease states. Its key drug, crofelemer, is the only oral FDA-approved prescription drug under botanical guidance, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. The company's approved product Mytesi (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Through its family of companies — Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. — the company is focused on developing a crofelemer powder-for-oral-solution formulation for rare and orphan gastrointestinal disorders involving intestinal failure, including microvillus inclusion disease (MVID) and short bowel syndrome. Jaguar also markets Gelclair for oral pain management and Canalevia-CA1, a conditionally FDA-approved treatment for chemotherapy-induced diarrhea in dogs. In January 2026, Jaguar licensed exclusive U.S. marketing rights for Mytesi and Canalevia-CA1 to Future Pak, shifting its commercial model to cost-plus supply while refocusing resources on rare disease drug development. Magdalena Biosciences, a joint venture with Filament Health Corp., is developing novel prescription medicines derived from plants for mental health indications. Updated Aug 19, 2026